Short description
Diffusion Pharmaceuticals develops small molecule therapeutics for treating life-threatening medical conditions.
Description
Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Charlottesville, Virginia, United States, North America
Founded on
January 1, 2001
Exited on
January 8, 2016
Went public on
January 8, 2016
Stock symbol
DFFN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Uh Ohhhh, Noaccess, Nopepepe, Cannot Access
Sign in for full access
Founders
David G. Kalergis, John L. Gainer